Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
ZypAdhera® (Olanzapine pamoate): Use in patients with COVID-19 (Coronavirus disease 2019)
The use of olanzapine long-acting injection in patients with COVID-19 has not been studied.
Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as "2019 novel coronavirus."1
Lilly has not studied the use of olanzapine long-acting injection in patients with COVID-19 nor in patients at risk of contracting COVID-19.
Warnings and Precautions
Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients
receiving medicines known to cause neutropenia, in patients with
with a history of drug-induced bone marrow depression/toxicity,
with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and
with hypereosinophilic conditions or with myeloproliferative disease.2
Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly.2
In addition, please note the following common adverse events (≥ 1/100 to < 1/10) that may occur in patients being treated with olanzapine pamoate. The following list includes adverse reactions observed from spontaneous reporting and in clinical trials. For full list of undesirable effects, please refer to section 4.8 of the ZypAdhera Summary of Product Characteristics.
Pyrexia (common) (As assessed by measured values from clinical trials in the Olanzapine Integrated Database.)2
Infectious Disease Resources
For the most current information regarding the coronavirus, please refer to the websites of local health authorities and/or the WHO website at WHO Coronavirus disease (COVID-19) outbreak.
1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed March 11, 2020.
CDC = The Center for Disease Control
Lilly = Eli Lilly and Company
WHO = World Health Organization
Date of Last Review: March 24, 2020